BioSpace News Archive

Shares of Edge Therapeutics were in free fall Wednesday afternoon following the company’s decision to discontinue development of a late stage treatment for adults with aneurysmal subarachnoid hemorrhage (aSAH).

Versant Ventures spinoff company Tempest Therapeutics secured $70 million in a Series B funding to advance the company’s immunotherapy pipeline.

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Solid Biosciences Inc. (“Solid” or the “Company”) (NASDAQ: SLDB) and certain of its officers, on behalf of shareholders who purchased Solid securities (1) in Solid’s initial public offering on or about January 25, 2018; or (2) on the open market from January 25, 2018 through March 14, 2018, inclusive (the “Class Period”).

The NCCN 23rd Annual Conference brought survivors, clinicians, specialists, investigators, nurses, patient advocates, and more to Orlando to advance cancer care worldwide.

Dragovic was previously Vice President, Ethics & Compliance Americas

- A significant resurgence from Big Pharma in the top 10 The eighth annual Pharmaceutical Innovation Index, released by IDEA Pharma today, sees AstraZeneca top the industry for the first time.

PTC Therapeutics, Inc. announced the pricing of a public offering of 4,000,000 shares of its common stock at a public offering price of $27.04 per share, before underwriting discounts.

The Public Health Agency of Canada is collaborating with provincial public health partners, the Canadian Food Inspection Agency and Health Canada to investigate an outbreak of Salmonella Enteritidis infections in four provinces with cases of human illness linked to poultry, including frozen raw breaded chicken products.

Heron Therapeutics, Inc. announced the pricing of an underwritten public offering of 6 million shares of its common stock, offered at a price of $26.00 per share.

ProMetic Life Sciences Inc. reported its fourth quarter and year ended December 31, 2017 highlights and financial results.